SkyePharma PLC Company Profile (NASDAQ:SKYEY)

About SkyePharma PLC

SkyePharma PLC logoSkyepharma PLC (Skyepharma) is a specialty pharmaceutical company. The Company is engaged in the development and delivery of oral and inhalation pharmaceutical products. The Company's products pipeline includes four inhalation products, 10 oral products, one topical product and one injectable product. The Company's products include flutiform, Exparel, Paxil CR, Sular, Diclofenacratiopharm, Madopar DR and Coruno, among others. The Company's product flutiform is a multi-dose pressurized metered dose inhaler, utilizing SkyeDry technology, containing steroid (fluticasone) and a beta agonist (formoterol). flutiform is indicated for the treatment of asthma. Exparel is a bupivacaine injectable product indicated for post-surgical pain management. The Product utilizes Pacira Pharmaceuticals' DepoFoam technology. The Company has approximately 10 approved oral products that are sold in over 80 countries.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SKYEY
  • CUSIP:
Key Metrics:
  • Previous Close: $6.28
  • 50 Day Moving Average: $6.62
  • 200 Day Moving Average: $6.01
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $N/A
Additional Links:

Analyst Ratings

Consensus Ratings for SkyePharma PLC (NASDAQ:SKYEY) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for SkyePharma PLC (NASDAQ:SKYEY)
No equities research coverage for this company has been tracked by


Earnings History for SkyePharma PLC (NASDAQ:SKYEY)
No earnings announcements for this company have been tracked by


Earnings Estimates for SkyePharma PLC (NASDAQ:SKYEY)
No earnings estimates for this company have been tracked by


Dividend History for SkyePharma PLC (NASDAQ:SKYEY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for SkyePharma PLC (NASDAQ:SKYEY)
No insider trades for this company have been tracked by


Latest Headlines for SkyePharma PLC (NASDAQ:SKYEY)
DateHeadline logoSkyePharma Plc : Neutral assessment on price but strong on fundamentals (NASDAQ:SKYEY) - June 2 at 4:18 PM logoSkyePharma Plc :SKYEY-US: Earnings Analysis: For the six months ended December 31, 2015 (NASDAQ:SKYEY) - March 21 at 2:35 PM logoSkyePharma Plc :SKYEY-US: Earnings Analysis: 2015 By the Numbers (NASDAQ:SKYEY) - March 21 at 11:59 AM logoMundipharma Appointed as Development and Marketing Partner for flutiform(R) in Mexico, Central and South America (NASDAQ:SKYEY) - January 28 at 2:25 AM logoSkyePharma Plc : Overvalued relative to peers, but may deserve another look (NASDAQ:SKYEY) - January 7 at 4:09 PM logoSkyePharma Plc – Value Analysis (US OTC:SKYEY) : October 28, 2015 (NASDAQ:SKYEY) - October 28 at 1:55 PM


SkyePharma PLC (NASDAQ:SKYEY) Chart for Thursday, August, 25, 2016

Last Updated on 8/25/2016 by Staff